Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Allergan, Gedeon Richter Unbowed By Cariprazine MDD Phase III Trial Failure

Executive Summary

Allergan and Gedeon Richter have hit a buffer in the development of their antipsychotic cariprazine in the additional indication of major depressive disorder, but they plan to proceed with a further pivotal trial, and mollified analysts with the announcement of a filing timeline to bolster the drug's label in schizophrenia.

You may also be interested in...

Allergan Confident Data Support Bipolar Depression Addition To Vraylar's Label

After recording its third positive pivotal trial in bipolar depression, Allergan will now file an sNDA for Vraylar in the second half of 2018.

Allergan Hopes To Add Bipolar Depression To Vraylar's Label

With Phase III success in bipolar depression, Allergan plans an sNDA in 2018 to add that indication to the atypical antipsychotic's label, which includes schizophrenia and bipolar mixed or manic episodes.

Uphill Climb For Gedeon Richter's Cariprazine After Delayed EU OK

Gedeon Richter has finally had its antipsychotic cariprazine approved in the EU for treating schizophrenia - but its delay to market could dampen demand for the drug unless it can differentiate itself from rivals.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts